Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients ...
- ARO-RAGE reduced serum sRAGE by up to 88% in patients with asthma - Additional promising results presented on two preclinical stage programs targeting thymic stromal lymphopoietin (TSLP) and influenza A viruses Arrowhead Pharmaceuticals, Inc. (NASDAQ: …